|
|
||||||||
From the Service de Neurologie (Dr. Clanet), CHU Toulouse Purpan, Toulouse, France; University Hospitals (Drs. Radue and Kappos), Departments of Neurology and Neuroradiology, Basel, Switzerland; Department of Neurology (Dr. Hartung), Heinrich-Heine-Universität, Düsseldorf, Germany; Neurology Clinic (Dr. Hohlfeld), Munich, Germany; Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; and Biogen, Inc. (Drs. Kooijmans-Coutinho, Tsao, and Sandrock), Cambridge, MA.
Address correspondence and reprint requests to Dr. Ludwig Kappos, Department of Neurology, University Hospitals, Petersgraben 4, Basel, CH-4031, Switzerland; e-mail: lkappos{at}uhbs.ch
Background: Interferon ß-1a (IFNß-1a; Avonex) is effective for the treatment of relapsing MS; however, the optimal dose of IFNß-1a is not known.
Objective: To determine whether IFNß-1a 60 µg IM once weekly is more effective than IFNß-1a 30 µg IM once weekly in reducing disability progression in relapsing MS.
Methods: In a double-blind, parallel-group, dose-comparison study, 802 patients with relapsing MS from 38 centers in Europe were randomized to IFNß-1a 30 µg (n = 402) or 60 µg (n = 400) IM once weekly for
36 months. The primary endpoint was disability progression, defined as time to a sustained increase of
1.0 point on the Expanded Disability Status Scale (EDSS) persisting for 6 months. Additional endpoints included relapses, MRI, safety, immunogenicity, and subgroup analyses of disability progression.
Results: Both groups showed equal rates of disability progression (hazard ratio, 0.96; 95% CI, 0.77 to 1.20; p = 0.73). In both groups the proportion of subjects with progression of disability by 36 months estimated from KaplanMeier curves was 37%. No dose effects were observed on any of the secondary clinical endpoints. Only one MRI measure at one time point, number of new or enlarging T2 lesions at month 36 compared with month 24, showed a difference favoring the 60-µg dose. Both doses were well tolerated; however, slightly higher incidences of flulike symptoms and muscle weakness were observed in the 60-µg group. The incidences of neutralizing antibodies (titers
20) were 2.3% in the 30-µg group and 5.8% in the 60-µg group.
Conclusion: There was no difference between IFNß-1a 30 µg and 60 µg IM in clinical or MRI measures.
This article has been cited by other articles:
![]() |
H. Wiendl and R. Hohlfeld Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes Neurology, March 17, 2009; 72(11): 1008 - 1015. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Cohen, P. B. Imrey, P. A. Calabresi, K. R. Edwards, T. Eickenhorst, W. L. Felton III, E. Fisher, R. J. Fox, A. D. Goodman, C. Hara-Cleaver, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS Neurology, February 10, 2009; 72(6): 535 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF] |
||||
![]() |
J. Killestein and H.-P. Hartung Interferon {beta} in multiple sclerosis: predicting response at an early stage J. Neurol. Neurosurg. Psychiatry, June 1, 2008; 79(6): 616 - 617. [Full Text] [PDF] |
||||
![]() |
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382. [Abstract] [PDF] |
||||
![]() |
R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218. [Abstract] [PDF] |
||||
![]() |
E. Le Page, E. Leray, G. Taurin, M. Coustans, J. Chaperon, S. P Morrissey, and G. Edan Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 52 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sorensen, N. Koch-Henriksen, and K. Bendtzen Are ex vivo neutralising antibodies against IFN-{beta} always detrimental to therapeutic efficacy in multiple sclerosis? Multiple Sclerosis, June 1, 2007; 13(5): 616 - 621. [Abstract] [PDF] |
||||
![]() |
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF] |
||||
![]() |
R. Zivadinov, L. Locatelli, D. Cookfair, B. Srinivasaraghavan, A. Bertolotto, M. Ukmar, A. Bratina, C. Maggiore, A. Bosco, A. Grop, et al. I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy Multiple Sclerosis, May 1, 2007; 13(4): 490 - 501. [Abstract] [PDF] |
||||
![]() |
S. E. Goelz and L. Walt Development of neutralizing antibodies to intramuscular interferon beta-1a (Avonex (R)) Multiple Sclerosis, May 1, 2007; 13(1_suppl): 14 - 20. [Abstract] [PDF] |
||||
![]() |
D. S. Goodin, E. M. Frohman, B. Hurwitz, P. W. O'Connor, J. J. Oger, A. T. Reder, and J. C. Stevens Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, March 27, 2007; 68(13): 977 - 984. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Sominanda, U Rot, M Suoniemi, F Deisenhammer, J Hillert, and A Fogdell-Hahn Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity Multiple Sclerosis, March 1, 2007; 13(2): 208 - 214. [Abstract] [PDF] |
||||
![]() |
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF] |
||||
![]() |
L. Kappos, A. Traboulsee, C. Constantinescu, J. -P. Eralinna, F. Forrestal, P. Jongen, J. Pollard, M. Sandberg-Wollheim, C. Sindic, B. Stubinski, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology, September 26, 2006; 67(6): 944 - 953. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Petersen, K. Bendtzen, N. Koch-Henriksen, M. Ravnborg, C. Ross, P. S. Sorensen, and The Danish Multiple Sclerosis Group Persistence of neutralizing antibodies after discontinuation of IFN{beta} therapy in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 247 - 252. [Abstract] [PDF] |
||||
![]() |
R. A. Rudick, W. H. Stuart, P. A. Calabresi, C. Confavreux, S. L. Galetta, E.-W. Radue, F. D. Lublin, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med., March 2, 2006; 354(9): 911 - 923. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bielekova, N. Kadom, E. Fisher, N. Jeffries, J. Ohayon, N. Richert, T. Howard, C. N. Bash, J. A. Frank, L. Stone, et al. MRI as a marker for disease heterogeneity in multiple sclerosis Neurology, October 11, 2005; 65(7): 1071 - 1076. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M Herndon, R. A Rudick, F. E Munschauer III, M. K Mass, A. M Salazar, M. E Coats, R. Labutta, J. R Richert, S. L Cohan, C. Genain, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex(R)treatment in patients with multiple sclerosis Multiple Sclerosis, August 1, 2005; 11(4): 409 - 419. [Abstract] [PDF] |
||||
![]() |
L. Kappos, M. Clanet, M. Sandberg-Wollheim, E. W. Radue, H. P. Hartung, R. Hohlfeld, J. Xu, D. Bennett, A. Sandrock, S. Goelz, et al. Neutralizing antibodies and efficacy of interferon {beta}-1a: A 4-year controlled study Neurology, July 12, 2005; 65(1): 40 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology, July 12, 2005; 65(1): 33 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Schwid, J. Thorpe, M. Sharief, M. Sandberg-Wollheim, K. Rammohan, J. Wendt, H. Panitch, D. Goodin, D. Li, P. Chang, et al. Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis: The EVIDENCE Study Arch Neurol, May 1, 2005; 62(5): 785 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
M S Freedman, G S Francis, E A. Sanders, G P. Rice, P O'Connor, G Comi, P Duquette, L Metz, T J Murray, J-P Bouchard, et al. Randomized study of once-weekly interferon {beta}-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study Multiple Sclerosis, February 1, 2005; 11(1): 41 - 45. [Abstract] [PDF] |
||||
![]() |
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans, M. Clanet, E. W. Radue, L. Kappos, and for the European IFNss-1a in Relapsing MS Dose Com Rate of brain atrophy in relapsing MS decreases during treatment with IFN{beta}-1a Neurology, January 25, 2005; 64(2): 236 - 240. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H. Stuart, S. Cohan, J. R. Richert, and A. Achiron Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S19 - S27. [Abstract] [Full Text] |
||||
![]() |
W. H. Stuart and P. Vermersch Concomitant therapy for multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S28 - S34. [Abstract] [Full Text] |
||||
![]() |
T. K. Vartanian, S. S. Zamvil, E. Fox, and P. S. Sorensen Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S42 - S49. [Abstract] [Full Text] |
||||
![]() |
C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, and F Deisenhammer Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity Multiple Sclerosis, October 1, 2004; 10(5): 507 - 510. [Abstract] [PDF] |
||||
![]() |
T L Vollmer, J T Phillips, A D Goodman, M A Agius, M A Libonati, J L Giacchino, and J S Grundy An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 511 - 520. [Abstract] [PDF] |
||||
![]() |
S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis Neurology, June 8, 2004; 62(11): 2031 - 2037. [Abstract] [Full Text] [PDF] |
||||
![]() |
O Andersen, I Elovaara, M Farkkila, H J Hansen, S I Mellgren, K-M Myhr, M Sandberg-Wollheim, and P Soelberg Sorensen Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 706 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Clanet, L Kappos, H-P Hartung, R Hohlfeld, and The European IFNss-1a Dose-Comparison Study Invest Interferon {beta}-1a in relapsing multiple sclerosis: four-year extension of the European IFN{beta}-1a Dose-C omparison Study Multiple Sclerosis, April 1, 2004; 10(2): 139 - 144. [Abstract] [PDF] |
||||
![]() |
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans-Coutinho, M. Clanet, E. W. Radue, and L. Kappos Atrophy Is Detectable Within a 3-Month Period in Untreated Patients With Active Relapsing Remitting Multiple Sclerosis Arch Neurol, December 1, 2003; 60(12): 1736 - 1739. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Salama, J. Hong, Y. C. Q. Zang, A. El-Mongui, and J. Zhang Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis Brain, December 1, 2003; 126(12): 2638 - 2647. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Giovannoni Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies Neurology, November 11, 2003; 61(90095): S13 - 17. [Abstract] [Full Text] |
||||
![]() |
M. Trojano, M. Liguori, D. Paolicelli, G. B. Zimatore, F. De Robertis, C. Avolio, F. Giuliani, A. Fuiani, P. Livrea, and Southern Italy MS Group Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy Multiple Sclerosis, October 1, 2003; 9(5): 451 - 457. [Abstract] [PDF] |
||||
![]() |
E. Byrne, H. Panitch, P. Coyle, D. Goodin, P. O'Connor, B. Weinshenker, D. Li, G. Francis, P. Chang, E. Monaghan, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial Neurology, June 10, 2003; 60(11): 1872 - 1873. [Full Text] [PDF] |
||||
![]() |
J.-M. Vallat, A.F. Hahn, J.-M. Leger, D.P. Cros, L. Magy, F. Tabaraud, P. Bouche, and P.-M. Preux Interferon beta-1a as an investigational treatment for CIDP Neurology, April 22, 2003; 60(90083): S23 - 28. [Abstract] [Full Text] |
||||
![]() |
F. D. Lublin When marketing and science intersect: Do patients with MS benefit? Neurology, November 26, 2002; 59(10): 1480 - 1481. [Full Text] [PDF] |
||||
![]() |
K. Kieburtz and M. McDermott Needed in MS: Evidence, not EVIDENCE Neurology, November 26, 2002; 59(10): 1482 - 1483. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |